Posco M-Tech Q3 Operating Profit Rises 45.13% Year-on-Year
Bitget2026/11/02 04:46- Posco M-Tech’s preliminary third-quarter 2026 operating profit fell 73.93% from the previous quarter to 2.52 billion won.
- Revenue rose 30.06% year over year to 107.79 billion won.
- Net income increased 197.36% from a year earlier to 3.96 billion won.
- January-September operating profit reached 14.67 billion won, reversing a year-earlier loss of 2.3 billion won.
- Nine-month net income totaled 13.93 billion won, compared with a loss of 3.04 billion won a year earlier.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
CleanSpark presents fully funded Sandersville project in investor presentation
Forge Nano completes acquisition of HzO
Crypto prices
More
